Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT05007782 Recruiting - Clinical trials for Advanced Solid Tumor

Study of GS-1811 Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

Start date: August 18, 2021
Phase: Phase 1
Study type: Interventional

This is a first-in-human (FIH) study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of GS-1811 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors. This study will be conducted in 6 parts (Parts A, B, and E: monotherapy, Parts C and D: combination therapy, and Part F for both monotherapy and combination therapy) in participants with advanced solid tumors who have received, been intolerant to, or been ineligible for all treatments known to confer clinical benefit or in participants with select solid tumors.

NCT ID: NCT05002270 Recruiting - Clinical trials for Advanced Solid Tumor

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

Start date: September 3, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.

NCT ID: NCT04999384 Recruiting - Clinical trials for Advanced Solid Tumor

First in Human, Dose Escalation Study of AN4005

Start date: September 27, 2021
Phase: Phase 1
Study type: Interventional

Open-label, multicenter, phase 1 study to investigate the safety, tolerability, and PK of AN4005 in patients with advanced tumors. This study is a first-in-human, dose escalation study with the objective to establish the MTD and/or RP2D of AN4005. Except for Dose Level 0 (50 mg), a traditional "3 + 3 design" will be utilized for dose finding with dose escalation and/or de-escalation as appropriate.

NCT ID: NCT04998422 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of HG381 Administered to Patients With Advanced Solid Tumors

Start date: October 18, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase I, first in human, open-label, non-randomized, multicenter study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary efficacy and establish a recommended dose of HG381 administered intravenously (IV) alone in subjects with advanced solid tumors.

NCT ID: NCT04990739 Recruiting - Clinical trials for Advanced Solid Tumor

Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors

Start date: June 30, 2021
Phase: Phase 1
Study type: Interventional

MetaboMed is developing MTB-9655, an orally bioavailable, first-in-class small molecule inhibitor of the human Acetyl coenzyme A (Acyl-CoA) synthetase short chain family member 2 (ACSS2) enzyme, as a potential treatment for patients with cancer. This study is a Phase 1,First-in-Human (FIH), open-label dose-escalation study of MTB-9655 given daily as a single oral (PO) agent. Up to 30 patients with locally advanced, unresectable and/or metastatic solid tumor(s) are expected to be enrolled in the dose-escalation portion (Part A). The study will be conducted at 1 to 2 sites in the United States and Israel.

NCT ID: NCT04986865 Recruiting - Clinical trials for Advanced Solid Tumor

A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

PROBE
Start date: December 15, 2021
Phase: Phase 1
Study type: Interventional

This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas.

NCT ID: NCT04977453 Recruiting - Clinical trials for Non-small Cell Lung Cancer

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

Start date: August 2, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab, lenvatinib or local radiotherapy (RT) over a range of advanced and/or metastatic solid tumors.

NCT ID: NCT04947033 Recruiting - Clinical trials for Advanced Solid Tumor

A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors

Start date: December 31, 2023
Phase: Phase 1
Study type: Interventional

A phase I clinical study evaluating TJ210001 in the treatment of subjects with advanced solid tumors

NCT ID: NCT04941339 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors

Start date: November 21, 2018
Phase: Phase 1
Study type: Interventional

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-positive advanced solid tumors.

NCT ID: NCT04936178 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of NB003 in Patients With Advanced Malignancies

Start date: August 6, 2021
Phase: Phase 1
Study type: Interventional

This a A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB003 in Subjects with Advanced Malignancies